AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Flu-based COVID-19 Vaccine

Summary

It is a flu-based nasal spray COVID-19 vaccine that could generate immunity against both flu and COVID-19.

Technology Benefits

Easy to use; Highly safe; provide both mucosal and systemic immune response

Technology Application

Vaccine

Detailed Technology Description

It is live attenuated with the deletion of the key virulent element and immune antagonist, NS1, from the viral genome and is potentially more immunogenic than wild type influenza virus. It uses flu vector to express a specific antigen to induce immunity targeting the critical element of the Receptor Binding Domain (RBD) of SARS-CoVs. Such strategy may avoid potential antibody dependent enhancement (ADE) as observed in the experimental vaccine for SARS-CoV.
It can be produced in chicken embryonated eggs and MDCK cells which are proven production systems for influenza vaccines. Its features are highly safe and is used as nasal spray to induce both local mucosal immune response and systemic immune response by simulating the natural infection pathway of respiratory viruses.

Type of Cooperation

Licensing

Application Date

10/02/2020 00:00:00

Application No.

US Provisional Application No. 62/972,616;

US Provisional Application No.63/037,645;

PCT/CN2021/075527

Classes

C09D 5/00

Country/Region

Hong Kong

For more information, please click Here